Log in

6938 Suzhou Ribo Life Science Co. Ltd. HKEX · China

Suzhou Ribo Life Science Co. (6938) news

Suzhou Ribo Life Science Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6938, recorded under China. The directory classifies it as Pharmaceuticals: Generic. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Suzhou Ribo Life Science Co. news

We have not published a story on Suzhou Ribo Life Science Co. yet. When there is news, it will appear here.

Questions about Suzhou Ribo Life Science Co.

What is the ticker symbol of Suzhou Ribo Life Science Co.?

Suzhou Ribo Life Science Co. Ltd. trades under the ticker 6938 on HKEX.

Where is Suzhou Ribo Life Science Co. listed?

Suzhou Ribo Life Science Co. Ltd. is listed on HKEX.

Which country or territory is Suzhou Ribo Life Science Co. listed under?

Our directory records Suzhou Ribo Life Science Co. Ltd. under China.

What does Suzhou Ribo Life Science Co. do?

Our directory classifies Suzhou Ribo Life Science Co. Ltd. as: Pharmaceuticals: Generic. This is a directory classification, not a description of the pipeline.

What is the ISIN of Suzhou Ribo Life Science Co.?

The ISIN recorded for Suzhou Ribo Life Science Co. Ltd. is CNE100007DS6.

Does aibio.space cover Suzhou Ribo Life Science Co.?

aibio.space lists Suzhou Ribo Life Science Co. Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Suzhou Ribo Life Science Co.?

Companies in our directory listed in the same country and business area as Suzhou Ribo Life Science Co.: Zhejiang Shouxiangu Pharmaceutical Holding Co., Tibet Duo Rui Pharmaceutical Co., Haisco Pharmaceutical Group Co., Vigonvita Life Sciences Co., Realcan Pharmaceutical Group Co., Chongqing Taiji Industry (Group) Co..

Investor discussion: Suzhou Ribo Life Science Co.

Members talk about Suzhou Ribo Life Science Co. (6938). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Suzhou Ribo Life Science Co., newest first. Each line links the filing it comes from.

  1. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE AND CONNECTED TRANSACTION ACQUISITION OF THE REMAINING 49.71% SHAREHOLDING IN A SUBSIDIARY INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; AND PROPOSED CHANGE OF REGISTERED CAPITAL AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source

  2. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25.93% EQUITY INTEREST IN AZEMIDITE. Source

  3. Financings

    Share or debt issue: CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING. Source

  4. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Suzhou Ribo Life Science Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    DISCLOSEABLE AND CONNECTED TRANSACTION ACQUISITION OF THE REMAINING 49.71% SHAREHOLDING IN A SUBSIDIARY INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; AND PROPOSED CHANGE OF REGISTERED CAPITAL AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL APPLICATION SUBMISSION OF RBD3133 INJECTION FOR OVERWEIGHT AND OBESITY

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX AND INCLUSION IN THE STOCK LIST OF STOCK CONNECT SOUTHBOUND TRADING LINK

  4. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  5. HKEXnews

    POSITIVE FINANCIAL INFORMATION ALERT

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - APPROVAL OF PHASE 2B CLINICAL TRIAL BY EMA OF CORE PRODUCT VORTOSIRAN FOR SPAF

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE 2A STUDY RESULTS OF CORE PRODUCT VORTOSIRAN FOR CAD

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE UNDER THE SHARE REPURCHASE MANDATE

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF H SHARES OF THE COMPANY BY A DIRECTOR

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF H SHARES OF THE COMPANY BY A DIRECTOR

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT - FIRST MILESTONE ACHIEVEMENT OF COLLABORATION WITH MADRIGAL

  12. HKEXnews

    DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25.93% EQUITY INTEREST IN AZEMIDITE

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE H SHARE INCENTIVE SCHEME AND ON-MARKET SHARE REPURCHASE

  14. HKEXnews

    Articles of Association

  15. HKEXnews

    POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL APPLICATION SUBMISSION OF RBD1119 INJECTION FOR TREATMENT OF CORONARY ARTERY DISEASE

  17. HKEXnews

    H Share Option Scheme

  18. HKEXnews

    H Share Incentive Scheme

  19. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  20. HKEXnews

    CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6938 on TradingView.

Listing details

Suzhou Ribo Life Science Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6938, recorded under China. The directory classifies it as Pharmaceuticals: Generic. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Suzhou Ribo Life Science Co. Ltd.
Ticker
6938
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Generic
ISIN
CNE100007DS6
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.